Get the Stockscreener App
16.36
7.77%
1.18
After Hours:
16.47
0.11
+0.67%
Uniqure N V stock is traded at $16.36, with a volume of 1.36M.
It is up +7.77% in the last 24 hours and down -34.22% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
See More
Previous Close:
$15.18
Open:
$15.62
24h Volume:
1.36M
Relative Volume:
0.42
Market Cap:
$1.02B
Revenue:
$16.10M
Net Income/Loss:
$-198.97M
P/E Ratio:
-4.6999
EPS:
-3.4809
Net Cash Flow:
$-183.99M
1W Performance:
+11.07%
1M Performance:
-34.22%
6M Performance:
-68.93%
1Y Performance:
+13.93%
1-Day Range:
$15.36
$16.96
1-Week Range:
$14.17
$17.72
52-Week Range:
$7.76
$71.50
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
16.36 | 949.20M | 16.10M | -198.97M | -183.99M | -3.4809 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Upgrade | Mizuho | Neutral → Outperform |
| Mar-09-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-09-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-03-26 | Downgrade | Mizuho | Outperform → Neutral |
| Mar-03-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Mar-02-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-24-26 | Initiated | Wolfe Research | Peer Perform |
| Jan-28-26 | Initiated | Barclays | Equal Weight |
| Nov-04-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-14-25 | Upgrade | Mizuho | Neutral → Outperform |
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
Levi & Korsinsky Reminds uniQure N.V. Investors of the Pending C - GuruFocus
Levi & Korsinsky Reminds uniQure N.V. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 13, 2026QURE - Morningstar
QURE Shareholder Alert: uniQure N.V. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm - Sahm
uniQure Faces Securities Fraud Lawsuit After FDA Approval Delay - National Today
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - GlobeNewswire Inc.
Gartner, Inc. Securities Fraud Class Action Result of Reduced Guidance Disclosure and 48% Stock Decline - GlobeNewswire Inc.
Driven Brands Holdings Inc. Securities Fraud Class Action Result of Erroneous Financial Statements and 39% Stock Decline - GlobeNewswire Inc.
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - GlobeNewswire Inc.
uniQure N.V. (QURE) Securities Fraud Class Action Lawsuit Filed; April 13, 2026, Lead Plaintiff Deadline - ChartMill
Liquidity Mapping Around (QURE) Price Events - Stock Traders Daily
uniQure Investors Sue Company Over Huntington’s Disease Drug Study Claims - TipRanks
UNIQURE N.V. (QURE) Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action - marketscreener.com
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Holzer & Holzer, LLC Reminds Investors of April 13, 2026 - GlobeNewswire
UniQure NV (NASDAQ:QURE) Q4 2025 earnings call transcript - MSN
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit - ChartMill
Barclays Maintains uniQure (QURE) Rating, Lowers Price Target | QURE Stock News - GuruFocus
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure Lawsuit – QURE - GlobeNewswire
uniQure (NASDAQ:QURE) Shares Down 4.9% After Analyst Downgrade - MarketBeat
Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
Barclays Maintains uniQure (QURE) Rating, Lowers Price Target | - GuruFocus
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. Investors - GlobeNewswire
QURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - Sahm
ROSEN, SKILLED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before ... - Bluefield Daily Telegraph
ROSEN, SKILLED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
uniQure N.V. (QURE) Class Action Lawsuit: Investors Face April 13, 2026, Deadline - The Globe and Mail
UniQure surges following departure of key FDA official - MSN
Market Review: What are the analyst revisions for JPMPRPCIs uniQure NV stock a good investment in YEARDividend Hike & Growth Focused Entry Point Reports - baoquankhu1.vn
Investment Recap: Can uniQure NV continue delivering strong returnsMarket Activity Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn
NASDAQ: QURE: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE) - The Globe and Mail
QURE stock crashes 32% in a week: Here's what you should know - MSN
QURE DEADLINE NOTICE: uniQure N.V. Investors Encouraged to Contact Kirby McInerney LLP By April 13, 2026 - ACCESS Newswire
uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V.QURE - Morningstar
uniQure Faces Investor Lawsuit Reminder - Intellectia AI
uniQure N.V. stock surges on positive Phase 1/ 2 data for AMT-130 in Huntington's disease - AD HOC NEWS
QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data - PR Newswire
Energy Moves: Does uniQure NV have strong fundamentals2026 Volume Leaders & Reliable Price Breakout Signals - baoquankhu1.vn
uniQure N.V. (QURE) Securities Fraud Class Action Lawsuit - GlobeNewswire
QURE INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - TMX Newsfile
uniQure N.V. $QURE Shares Sold by JPMorgan Chase & Co. - MarketBeat
uniQure N.V. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights - Benzinga
QURE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data - GlobeNewswire Inc.
Kessler Topaz Meltzer & Check, LLP Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE); April 13, 2026, Lead Plaintiff Deadline – Company AnnouncementFT.com - Financial Times
uniQure N.V. Stockholders Should Contact Robbins LLP for Information About Leading the QURE Class Action - PharmiWeb.com
UNIQURE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. ... - Bluefield Daily Telegraph
UNIQURE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
uniQure (NASDAQ:QURE) Shares Up 5%Still a Buy? - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming DeadlinesQURE - PR Newswire
QURE DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - ChartMill
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds uniQure N.V. Investors of ... - Bluefield Daily Telegraph
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):